TNYA — Tenaya Therapeutics Share News
0.000.00%
Last trade - 00:00U.S. RESEARCH ROUNDUP-Dick's Sporting Goods, Nvidia, PVH
Brief: Tenaya Therapeutics Q4 Net Income USD -29.935 Million
Brief: Tenaya Therapeutics Announces Pricing Of Underwritten Offering
Brief: Tenaya Therapeutics Q3 Net Income USD -29.143 Million
Brief: Tenaya Therapeutics Announces FDA Clearance To Begin Clinical Testing Of TN-401 Gene Therapy
Brief: Tenaya Therapeutics Presents Encouraging New Data For The Potential Treatment Of Heart Failure
Brief: Tenaya Therapeutics Doses First Patient In The Mypeak-1™ Phase 1B Clinical Trial Of TN-201 For The Treatment Of MYBPC3-Associated Hypertrophic Cardiomyopathy
Brief: Tenaya Therapeutics Reports First Quarter 2023 Financial Results And Provides Business Update
Brief: Tenaya Therapeutics Q1 basic loss per share USD 0.43
Brief: Tenaya Therapeutics Receives FDA Fast Track Designation For TN-201
Brief: Tenaya Therapeutics Inc Believes Its Exposure To Loss Due To Svb’S Receivership To Be Immaterial
Brief: Tenaya Therapeutics Reports Q4 And FY22 Financial Results
Brief: Tenaya Therapeutics Reports Q4 Loss Per Share Of $0.61
Analysis: Biotech IPOs to bloom with spotlight on startups with human trial data
Tenaya rises as FDA allows human trials for heart disease therapy
Brief: Tenaya Therapeutics Announces TN-201 IND Clearance And Anticipated 2023 Milestones
U.S. STOCKS ON THE MOVE-Talkspace, Flora Growth, Grindr Inc
U.S. STOCKS ON THE MOVE-Builders FirstSource, Tenaya Therapeutics, Blue Apron
Tenaya Therapeutics up as heart disorder drug gets 'orphan' designation